Aligos Therapeutics Report issue

For profit Phase 1
Founded: South San Francisco CA United States (2018)

Organization Overview

First Clinical Trial
2020
NCT04485663
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Aligos Therapeutics

Active Ingredients

Drugs in Phase 1 Trials (4)

alg-000184 (1 trial)

alg-010133 (1 trial)

alg-020572 (1 trial)

alg-055009 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 1)

Hepatitis B (Phase 1)

Hepatitis B, Chronic (Phase 1)

Hepatitis, Chronic (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 4
  • # of Trial APIs: 4